Home > Search Results

Results: 1 to 20 of 59

Clear

This summary of a Cochrane review presents what we know from research about the effect of abatacept on rheumatoid arthritis. Although expensive, if supported by the overall body of evidence, the claims of their benefit upon both symptoms and radiographic progression, and their low rate of short term side effects make them of great interest to patients with RA.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2010

Study found that for the treatment of rheumatoid arthritis, biologic disease-modifying antirheumatic drugs had cost per quality-adjusted life-year values greater than the thresholds stated by the National Institute for Health and Care Excellence and could not be considered cost-effective.

Health Technology Assessment - NIHR Journals Library.

Version: April 2016

Rheumatoid arthritis (RA) is an inflammatory condition that typically causes a symmetrical chronic arthritis. Timely use of disease-modifying antirheumatic drugs (DMARDs) is an essential aspect of disease management, but many patients may not respond even when conventional agents are used optimally.

Health Technology Assessment - NIHR Journals Library.

Version: March 2011

The study found that biologic disease-modifying antirheumatic drugs (with methotrexate where permitted) are superior to placebo in children with polyarticular course JIA who have had an insufficient response to previous treatment.

Health Technology Assessment - NIHR Journals Library.

Version: April 2016

Bibliographic details: Venson R, Wiens A, Correr CJ, Pontarolo R.  Efficacy, safety and tolerability of using abatacept for the treatment of rheumatoid arthritis. Brazilian Journal of Pharmaceutical Sciences 2012; 48(4): 781-791 Available from: http://www.scielo.br/scielo.php?pid=S1984-82502012000400022&script=sci_arttext

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2012

Rheumatoid arthritis (RA) is a common inflammatory condition that typically causes a symmetrical chronic arthritis that causes joint pain, swelling and in some cases a systemic illness. The cause of RA is unknown, but important genetic influences are recognised. The goal of treatment is to achieve remission if patients present with early disease. In later disease, key goals are to control pain and inflammation and thereby reduce functional limitations and the risk of permanent joint damage.

NIHR Health Technology Assessment programme: Executive Summaries - NIHR Journals Library.

Version: 2011

OBJECTIVE: To identify if rheumatoid factor (RF) is predictor of response to rituximab (RTX), abatacept (ABT), and tocilizumab (TCZ) in rheumatoid arthritis (RA).

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2013

Kidney transplants can improve the quality and length of life for patients with end‐stage kidney disease (ESKD) compared with chronic dialysis. To prevent a kidney transplant from being rejected by the body, immune‐system suppressing drugs (most commonly a calcineurin inhibitors (CNI)) are used. CNI are associated with high blood pressure, high lipid levels, an increased risk of developing diabetes, and chronic scarring of the kidney transplant. Chronic kidney scarring is the main reason that kidney transplants lose function in people who do not die before their kidney transplant fails. Belatacept might be an alternative immune‐system suppressing drug which prevents rejection but which also causes fewer side‐effects than CNI.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2014

This summary of a Cochrane review presents what we know from research about the effect of biologics on Rheumatoid Arthritis (RA).

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2013

INTRODUCTION: The goal of this study was to compare the efficacy in terms of Health Assessment Questionnaire change from baseline (HAQ CFB), 50% improvement in American College of Rheumatology criterion (ACR-50) and Disease Activity Score in 28 joints (DAS28) defined remission (< 2.6) between abatacept and other biologic disease modifying anti-rheumatic drugs (DMARDs) in patients with rheumatoid arthritis (RA) who have inadequate response to methotrexate (MTX-IR).

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2011

BACKGROUND: Rheumatoid arthritis (RA) is an inflammatory condition that typically causes a symmetrical chronic arthritis. Timely use of disease-modifying antirheumatic drugs (DMARDs) is an essential aspect of disease management, but many patients may not respond even when conventional agents are used optimally.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2011

OBJECTIVE: To review the clinical evidence on subcutaneous (sc) abatacept and to formulate recommendations in order to clear up points related to its use in rheumatology.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2014

This review evaluated the effects of biological agents on the risk of serious infections in patients with rheumatoid arthritis, concluding that rituximab or abatacept treatment did not increase the risk of serious infections, although high doses of anakinra may increase the risk, especially in patients with comorbidities. Some reporting limitations make it difficult to determine the reliability of these conclusions.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2009

The authors concluded that abatacept plus methotrexate improved functional status compared with placebo plus methotrexate in UK rheumatoid arthritis patients previously unresponsive to methotrexate. Given differences between included trials, the potential for language bias, and the potential for bias in some included trials, the reliability of the authors' conclusions is unclear.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2012

The aims of the present investigation were ■ to assess the benefit of treatment with biotechnologically produced drugs compared with each other ■ to assess the benefit of treatment with biotechnologically produced drugs compared with treatment with non-biotechnologically produced drugs, as well as ■ to assess the benefit of treatment with biotechnologically produced drugs compared with treatment without therapy extension (with or without placebo control) in each case as second-line therapy in patients with RA. The assessment was based on patient-relevant outcomes.

Institute for Quality and Efficiency in Health Care: Executive Summaries [Internet] - Institute for Quality and Efficiency in Health Care (IQWiG).

Version: June 28, 2013

When you have rheumatoid arthritis, your immune system, which normally fights infection, attacks the lining of your joints, causing swelling, stiffness and pain. The small joints of your hands and feet are usually affected first. There is no cure for rheumatoid arthritis at present, so treatments aim to relieve pain and stiffness and improve your ability to move. Biologics are medications that can reduce joint inflammation, improve symptoms and prevent joint damage.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2016

We studied the benefits and harms of biologics or tofacitinib on people with rheumatoid arthritis (RA) who have not previously been treated with methotrexate (MTX), in trials done until June 2015. Data was available for four TNF biologics (adalimumab, etanercept, golimumab, infliximab) and two non‐TNF biologics (abatacept, rituximab).

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: May 8, 2017

Compare the benefits and harms of corticosteroids, oral and biologic disease-modifying antirheumatic drugs (DMARDs) for adults with rheumatoid arthritis.

Comparative Effectiveness Reviews - Agency for Healthcare Research and Quality (US).

Version: April 2012

Rheumatoid arthritis (RA) is a chronic, inflammatory disease characterized by joint swelling, joint tenderness, and destruction of synovial joints, leading to severe disability and premature mortality. Disease prevalence in Canada is about 1% (0.9% in 2010), and it is expected to increase to 1.3% by 2040.

Common Drug Review - Canadian Agency for Drugs and Technologies in Health.

Version: July 2015

Juvenile idiopathic arthritis (JIA) is a relatively common, chronic childhood disorder, with clinical manifestations mainly related to joint inflammation and including joint effusion, joint line tenderness and warmth, restricted range of movement, and limitation of movement secondary to pain. Systemic onset JIA (sJIA) is a subtype of the disease accounting for approximately 4% to 15% of patients, and is defined as arthritis in one or more joints for at least 6 weeks in a child younger than 16 years with or preceded by fever of at least 2 weeks that is documented to be daily for at least 3 days and accompanied by one or more of the following: evanescent erythematous rash, generalized lymphadenopathy, hepatomegaly or splenomegaly, and serositis. Patients with sJIA experience an intense inflammatory state leading to a particularly refractory course and persistent disease. As a result, these patients are at high risk for serious complications such as joint damage and growth impairment, as well as macrophage activation syndrome (MAS), a life-threatening complication developing in 10% to 15% of children with sJIA and associated with a mortality rate that may reach 20%.

Common Drug Review - Canadian Agency for Drugs and Technologies in Health.

Version: November 2016

Systematic Reviews in PubMed

See all (164)...

Systematic Review Methods in PubMed

See all (1)...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...